166 related articles for article (PubMed ID: 21303336)
1. Epidemiology and prevention of bacterial infections in patients with hematologic malignancies.
Tessier J; Sifri CD
Infect Disord Drug Targets; 2011 Feb; 11(1):11-7. PubMed ID: 21303336
[TBL] [Abstract][Full Text] [Related]
2. Management of infections during intensive treatment of hematologic malignancies.
Maschmeyer G; Hiddemann W; Link H; Cornely OA; Buchheidt D; Glass B; Adam D
Ann Hematol; 1997; 75(1-2):9-16. PubMed ID: 9322678
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis and treatment of bacterial infections: do we need new strategies?
Micozzi A; Bucaneve G
Rev Clin Exp Hematol; 2005 Dec; 9(2):E4. PubMed ID: 16864118
[TBL] [Abstract][Full Text] [Related]
4. Counterpoint: routine anti-bacterial prophylaxis is not indicated in neutropenic patients with hematological malignancies.
Kleinberg M
J Natl Compr Canc Netw; 2004 Sep; 2(5):445-51. PubMed ID: 19780253
[TBL] [Abstract][Full Text] [Related]
5. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
Tamura K
Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
[TBL] [Abstract][Full Text] [Related]
6. [Role of daptomycin in the treatment of infections in patients with hematological malignancies].
Salavert M; Calabuig E
Med Clin (Barc); 2010 Dec; 135 Suppl 3():36-47. PubMed ID: 21477703
[TBL] [Abstract][Full Text] [Related]
7. Cefpodoxime for antimicrobial prophylaxis in neutropenia: a retrospective case series.
Wojenski DJ; Barreto JN; Wolf RC; Tosh PK
Clin Ther; 2014 Jun; 36(6):976-81. PubMed ID: 24832560
[TBL] [Abstract][Full Text] [Related]
8. Use of antibacterial prophylaxis for patients with neutropenia. Australian Consensus Guidelines 2011 Steering Committee.
Slavin MA; Lingaratnam S; Mileshkin L; Booth DL; Cain MJ; Ritchie DS; Wei A; Thursky KA;
Intern Med J; 2011 Jan; 41(1b):102-9. PubMed ID: 21272174
[TBL] [Abstract][Full Text] [Related]
9. Current treatments for infection in neutropenic patients with hematologic malignancy.
Greene JN; Linch DC; Miller CB
Oncology (Williston Park); 2000 Aug; 14(8 Suppl 6):31-4. PubMed ID: 10989822
[TBL] [Abstract][Full Text] [Related]
10. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Fever and neutropenia: the early years.
Bodey GP
J Antimicrob Chemother; 2009 May; 63 Suppl 1():i3-13. PubMed ID: 19372179
[TBL] [Abstract][Full Text] [Related]
11. [Antimicrobial prophylaxis and therapy in neutropenia].
Link H
Mycoses; 2003; 46 Suppl 2():21-32. PubMed ID: 15055140
[TBL] [Abstract][Full Text] [Related]
12. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why empirical therapy?
Klastersky J
J Antimicrob Chemother; 2009 May; 63 Suppl 1():i14-5. PubMed ID: 19372173
[TBL] [Abstract][Full Text] [Related]
13. A review of chemoprophylaxis and therapy of bacterial infections in neutropenic patients.
Klastersky J
Diagn Microbiol Infect Dis; 1989; 12(4 Suppl):201S-207S. PubMed ID: 2686921
[TBL] [Abstract][Full Text] [Related]
14. Clinical Features and Risk Factors for Development of Breakthrough Gram-Negative Bacteremia during Carbapenem Therapy.
Lee JY; Kang CI; Ko JH; Lee WJ; Seok HR; Park GE; Cho SY; Ha YE; Chung DR; Lee NY; Peck KR; Song JH
Antimicrob Agents Chemother; 2016 Nov; 60(11):6673-6678. PubMed ID: 27572416
[TBL] [Abstract][Full Text] [Related]
15. Early versus late onset bloodstream infection during neutropenia after high-dose chemotherapy for hematologic malignancy.
Widmer AF; Kern WV; Roth JA; Dettenkofer M; Goetting T; Bertz H; Theilacker C;
Infection; 2019 Oct; 47(5):837-845. PubMed ID: 31187401
[TBL] [Abstract][Full Text] [Related]
16. [From epidemiology to therapeutic choices. Infections in patients with neutropenia].
Cordonnier C; Dhedin N; Rieux C; Belhadj K
Presse Med; 1997 Jan 18-25; 26(1):45-50. PubMed ID: 9082406
[TBL] [Abstract][Full Text] [Related]
17. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Summary and comments.
Sinkó J; Kullberg BJ; Edwards JE; Anaissie E
J Antimicrob Chemother; 2009 May; 63 Suppl 1():i41-3. PubMed ID: 19372182
[No Abstract] [Full Text] [Related]
18. Secondary Infections in Febrile Neutropenia in Hematological Malignancies: More Than Another Febrile Neutropenic Episode.
Demirel A; Tabak F; Ar MC; Mete B; Öngören Ş; Yemişen M; Özaras R; Eşkazan E; Başlar Z; Mert A; Soysal T; Ferhanoğlu B; Aydın Y; Öztürk R
Turk J Haematol; 2015 Sep; 32(3):243-50. PubMed ID: 25913035
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial Prophylaxis and Preemptive Approaches for the Prevention of Infections in the Stem Cell Transplant Recipient, with Analogies to the Hematologic Malignancy Patient.
Neofytos D
Infect Dis Clin North Am; 2019 Jun; 33(2):361-380. PubMed ID: 31005133
[TBL] [Abstract][Full Text] [Related]
20. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group.
Cordonnier C; Herbrecht R; Pico JL; Gardembas M; Delmer A; Delain M; Moreau P; Ladeb S; Nalet V; Rollin C; Gres JJ
Clin Infect Dis; 1997 Jan; 24(1):41-51. PubMed ID: 8994754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
